S-1/A: Synergy CHC Corp. Files Amendment No. 7 to Form S-1 for Proposed IPO

Synergy CHC Corp. is moving forward with its IPO plans, offering 1,000,000 shares of common stock with an estimated price range of $9.00 to $11.00.

Summary

• Synergy CHC Corp. has filed Amendment No. 7 to its Form S-1 registration statement with the SEC.
• The company plans to offer 1,000,000 shares of its common stock to the public.
• The estimated initial public offering price is between $9.00 and $11.00 per share.
• The company has applied to list its common stock on the Nasdaq Global Market under the symbol SNYR.
• Upon completion of the offering, officers and directors will hold approximately 54% of the voting power.
• The company's flagship brand is FOCUSfactor, a brain health supplement, and its second marquee brand is Flat Tummy, a lifestyle and wellness brand.
• For the year ended December 31, 2023, FOCUSfactor represented 87% of the company's net revenue and Flat Tummy was 13%.
• Net revenue for the year ended December 31, 2023 was $42.8 million, an increase of 11% over 2022.
• Net revenue for the six months ended June 30, 2024 was $17.4 million, a decrease of 7.0% over the same period in 2023.
• The company intends to use the net proceeds of the offering to repay a portion of outstanding amounts under certain related party promissory notes and for general corporate purposes.

Sentiment

Score: 6

Explanation: The document presents a mixed sentiment. While there's positive historical revenue growth and plans for future expansion, there are also concerns about recent revenue decline, working capital deficit, and reliance on a few key customers. The company's debt and related party transactions add complexity.

Positives

• The company has experienced revenue growth, with net revenue increasing by 11% in 2023.
• FOCUSfactor has been tested in a single-center, randomized, double-blind, placebo-controlled, parallel group study to evaluate its effect on memory, concentration, and focus in healthy adults.
• The company has a scalable and flexible asset-light model to support growth.
• The company has premier retail partners including Costco, Walmart, Amazon.com, Walgreens, and CVS.
• The company has expanded internationally into Canada and the UK and anticipates being in Taiwan and Mexico in the second quarter of 2025 and in Australia and Asia in the first quarter of 2026.

Negatives

• Net revenue for the six months ended June 30, 2024 was $17.4 million, a decrease of 7.0% over the same period in 2023.
• The company had a working capital deficit of $3.8 million as of June 30, 2024.
• The company's capital structure has been highly levered.
• The company depends on a small number of large retailers for a significant portion of its sales.

Risks

• The company operates in a highly competitive industry.
• The company's sales growth is dependent upon maintaining relationships with a small number of existing large customers.
• The company may experience product recalls, withdrawals or seizures.
• The company and its suppliers are subject to numerous laws and regulations.
• The price of the company's common stock may be volatile.
• The company may need to raise additional capital in the future, and its failure to do so could restrict its operations or adversely affect its ability to operate and continue its business.

Future Outlook

The company intends to use the proceeds from the IPO to accelerate the growth of its FOCUSfactor supplements and energy RTD products, and to expand into new markets such as Taiwan, Mexico, Australia and Asia.

Industry Context

The global nutritional supplement market is expected to grow at a CAGR of approximately 9.3% from 2018 to 2028. The brain health supplement market was estimated to be $8.6 billion in 2022 and is expected to grow at a CAGR of 13.3% from 2023 to 2030.

Comparison to Industry Standards

• The document mentions competitors like Celsius, Bang, Reign, and C4 in the energy RTD category.
• It also references Celsius and Beyond Raw as examples of dual-benefit products delivering fat burning plus energy, and C4 Smart Energy and FocusAid delivering focus plus energy.
• The document states that FOCUSfactor's growth in the year ended December 31, 2023 was 17% year-over-year, significantly outpacing the overall brain health supplement market.

Legal Proceedings

• The company settled a lawsuit with Barbara Valenti in December 2022 for $340,000.
• The company settled a lawsuit with HVL, LLC d/b/a Atrium Innovations during December 2023, resulting in a net gain to the company of $2,235,986.
• The company settled a lawsuit with L.O.D.C. Group during April 2024.

Related Party Transactions

• The company has a Sales and Marketing Consultant and Distribution Agreement with Kenek Brands Inc., a company owned by Jack Ross, the Chief Executive Officer.
• The company has a Loan Agreement with Knight Therapeutics (Barbados) Inc., an affiliate of an owner of greater than 10% of the company's outstanding common stock.
• The company has distribution agreements with Knight Therapeutics, Inc. and Knight Therapeutics International S.A. for the distribution rights of FOCUSfactor, Hand MD, and Sneaky Vaunt in Canada, Israel, Romania, Russia and Sub-Saharan Africa.
• The company entered into transactions with BoomBod Ltd., a related party 100% indirectly owned by Jack Ross, the Chief Executive Officer.
• The company entered into transactions with Gowan Properties Inc., a related party 100% indirectly owned by Jack Ross, the Chief Executive Officer.

Stakeholder Impact

• The IPO will provide capital for the company to grow its brands and expand into new markets, which could benefit shareholders.
• The company's success depends on maintaining relationships with key retailers, which impacts suppliers and customers.
• The company's ability to comply with regulations impacts its ability to sell products, which affects customers and suppliers.
• The company's reliance on contract manufacturers impacts its ability to supply products, which affects customers.

Next Steps

• The company anticipates a coordinated expansion of its advertising strategy towards the end of 2024.
• The company plans to enter the Taiwan and Mexico markets in the second quarter of 2025 and in Australia and Asia in the first quarter of 2026.
• The major retailer will be re-launching the RTDs at the end of 2024.
• In 2025, the company plans to introduce an additional FOCUSfactor supplement for Taiwan, RTDs for the UK and focus and energy coffee for the United States.
• In the third quarter of 2024, the company looks to introduce new graphics for the FOCUSfactor line that provide a more impactful design.
• In the fourth quarter of 2024, the company plans on introducing new complementary products to the Flat Tummy line-up, including new protein shakes, gut-healthy ready-to-drink beverage, hydration powder and pre-workout powder.

Key Dates

Keywords

IPO, common stock, FOCUSfactor, Flat Tummy, nutritional supplements, consumer health, offering, SNYR, EBITDA, revenue